Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma

Pooja Shah, Thorsten Stuehmer, Larissa Haertle, Daniela Bruennert, Umair Munawar, Ellen Leich, Sabrina Kraus, Michael Hudecek, Manik Chatterjee, Andreas Schlosser, Martin Kortuem, Ralf C Bargou, Hermann Einsele, Friederike Berberich-Siebelt, Torsten Steinbrunn

Blood (2022) 140 (Supplement 1): 7076–7077.

https://doi.org/10.1182/blood-2022-166283

Published: 2022

Journal Articles

CD200 Expression on Multiple Myeloma Cells Induces Attenuation of T Cell-Mediated Cytotoxicity Via DOK2

Pooja Shah, Thorsten Stuehmer, Daniela Bruennert, Umair Munawar, Ellen Leich, Sabrina Kraus, Michael Hudecek, Manik Chatterjee, Andreas Schlosser, Ralf C Bargou, Hermann Einsele, Friederike Berberich-Siebelt, Torsten Steinbrunn

Blood (2021) 138 (Supplement 1): 1587.

https://doi.org/10.1182/blood-2021-153741

Published: 2021

Journal Articles

Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML

Martin Wermke, Sabrina Kraus, Armin Ehninger, Ralf C. Bargou, Maria-Elisabeth Goebeler, Jan Moritz Middeke, Carla Kreissig, Malte von Bonin, Jan Koedam, Michael Pehl, Martin Bornhäuser, Hermann Einsele, Gerhard Ehninger, Marc Cartellieri

Blood (2021) 137 (22): 3145–3148.

https://doi.org/10.1182/blood.2020009759

Published: 2021

Journal Articles

Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137350

Published: 2020

Journal Articles

Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness

Blood (2019) 134 (10): 836–840.

https://doi.org/10.1182/blood.2019000080

Published: 2019

Includes: Supplemental data

Journal Articles

Activated Ral and Mutated RAS Are Independent Drivers of Multiple Myeloma Cell Survival.

Marcel Seibold, Thorsten Stuehmer, Anja Mottok, Claus J Scholz, Manik Chatterjee, Ellen Leich, Martin Kortüm, Andreas Schlosser, Hermann Einsele, Andreas Rosenwald, Ralf C Bargou, Torsten Steinbrunn

Blood (2018) 132 (Supplement 1): 3217.

https://doi.org/10.1182/blood-2018-99-119804

Published: 2018

Journal Articles

Health-Related Quality of Life in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia and Minimal Residual Disease Treated with Blinatumomab

Ralf C Bargou, Gerhard Zugmaier, Massimiliano Bonifacio, Carlos Graux, Christoph Faul, MD, Max S. Topp, Qui Tran, Xinke Zhang, Nicola Goekbuget, MD

Blood (2018) 132 (Supplement 1): 1377.

https://doi.org/10.1182/blood-2018-99-112259

Published: 2018

Journal Articles

Implications of TP53 alterations for Therapy Response in Multiple Myeloma

Umair Munawar, MS, BS, Santiago Barrio, PhD, Markus Roth, Hermann Einsele, MD, Ralf C Bargou, Thorsten Stuehmer, Martin Kortum, MD

Blood (2018) 132 (Supplement 1): 3189.

https://doi.org/10.1182/blood-2018-99-118658

Published: 2018

Journal Articles

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio, Albrecht Reichle, Carlos Graux, Christoph Faul, Helmut Diedrich, Max S. Topp, Monika Brüggemann, Heinz-August Horst, Violaine Havelange, Julia Stieglmaier, Hendrik Wessels, Vincent Haddad, Jonathan E. Benjamin, Gerhard Zugmaier, Dirk Nagorsen, Ralf C. Bargou

Blood (2018) 131 (14): 1522–1531.

https://doi.org/10.1182/blood-2017-08-798322

Published: 2018

Includes: Supplemental data

Journal Articles

RAL Mediates Multiple Myeloma Cell Survival Independently of Oncogenic RAS

Marcel Seibold, Thorsten Stuehmer, Nadine Kremer, Anja Mottok, MD PhD, Claus J Scholz, Daniela Bruennert, Manik Chatterjee, Ellen Leich, Andreas Schlosser, Andreas Rosenwald, Hermann Einsele, Ralf C Bargou, Torsten Steinbrunn

Blood (2017) 130 (Supplement 1): 4406.

https://doi.org/10.1182/blood.V130.Suppl_1.4406.4406

Published: 2017

Journal Articles

Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking

Friederike Braig, Anna Brandt, Mariele Goebeler, Hans-Peter Tony, Anna-Katharina Kurze, Peter Nollau, Thomas Bumm, Sebastian Böttcher, Ralf C. Bargou, Mascha Binder

Blood (2017) 129 (1): 100–104.

https://doi.org/10.1182/blood-2016-05-718395

Published: 2017

Includes: Supplemental data

Journal Articles

Pathogenesis-Based Development of Potential Mitigation Strategies for Blinatumomab-Associated Neurologic Events (NEs)

Matthias Klinger, PhD, Gerhard Zugmaier, MD, Virginie Naegele, PhD, Mariele Goebeler, MD, Christian Brandl, MS, Ralf C Bargou, MD, Peter Kufer, MD

Blood (2016) 128 (22): 1589.

https://doi.org/10.1182/blood.V128.22.1589.1589

Published: 2016

Journal Articles

Parallel Evolution of Multiple PSMB5 mutations in a Myeloma Patient Treated with Bortezomib

Santiago Barrio, PhD, Thorsten Stühmer, PhD, Eva Teufel, Clara Barrio-Garcia, Manik Chatterjee, MD, Martin Schreder, MD, Mithun Das Gupta, MD, Andreas Rosenwald, MD, Raoul Tibes, MD PhD, Esteban Braggio, PhD, A. Keith Stewart, MD, Ralf C Bargou, MD, Hermann Einsele, MD, K Martin Kortüm, MD

Blood (2016) 128 (22): 3282.

https://doi.org/10.1182/blood.V128.22.3282.3282

Published: 2016

Journal Articles

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

Andreas Viardot, Marie-Elisabeth Goebeler, Georg Hess, Svenja Neumann, Michael Pfreundschuh, Nicole Adrian, Florian Zettl, Martin Libicher, Cyrus Sayehli, Julia Stieglmaier, Alicia Zhang, Dirk Nagorsen, Ralf C. Bargou

Blood (2016) 127 (11): 1410–1416.

https://doi.org/10.1182/blood-2015-06-651380

Published: 2016

Includes: Supplemental data

Journal Articles

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Gerhard Zugmaier, Nicola Gökbuget, Matthias Klinger, Andreas Viardot, Matthias Stelljes, Svenja Neumann, Heinz-A. Horst, Reinhard Marks, Christoph Faul, Helmut Diedrich, Albrecht Reichle, Monika Brüggemann, Chris Holland, Margit Schmidt, Hermann Einsele, Ralf C. Bargou, Max S. Topp

Blood (2015) 126 (24): 2578–2584.

https://doi.org/10.1182/blood-2015-06-649111

Published: 2015

Includes: Supplemental data

Journal Articles

Bispecific T-Cell Engager Antibody Construct Blinatumomab Shows Durable Response in a Long-Term Follow-up Analysis of 38 NHL Patients Treated in a Phase I Trial

Vera Dufner, Maria-Elisabeth Goebeler, Cyrus Sayheli, Ralf C. Bargou

Blood (2015) 126 (23): 3974.

https://doi.org/10.1182/blood.V126.23.3974.3974

Published: 2015

Journal Articles

Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

Nicola Gökbuget, MD, Hervé Dombret, MDPhD, Massimiliano Bonifacio, MD, Albrecht Reichle, MD, Carlos Graux, MDPhD, Christoph Faul, MD, Helmut Diedrich, MD, Max S. Topp, MD, Monika Brüggemann, MD, Heinz A. Horst, MD PhD, Julia Stieglmaier, PhD, Hendrik Wessels, MD, Vincent Haddad, MSc, Gerhard Zugmaier, MD, Dirk Nagorsen, MD, Ralf C Bargou, MD

Blood (2015) 126 (23): 680.

https://doi.org/10.1182/blood.V126.23.680.680

Published: 2015

Journal Articles

Treatment with Anti-CD19 BiTE ® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation

Anthony Selwyn Stein, MD, Max S. Topp, MD, Hagop M Kantarjian, MD, Nicola Goekbuget, MD, Ralf C Bargou, MD, Mark R Litzow, MD, Alessandro Rambaldi, MD, Josep Ribera, MD PhD, Alicia Zhang, PhD, Zachary Zimmerman, MD PhD, Stephen J. Forman, MD

Blood (2015) 126 (23): 861.

https://doi.org/10.1182/blood.V126.23.861.861

Published: 2015

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE ® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

Anthony Stein, Max S. Topp, Nicola Goekbuget, Ralf C. Bargou, Hervé Dombret, Adele K. Fielding, Richard A. Larson, Alessandro Rambaldi, Gary Schiller, MD, Gerhard Zugmaier, Catherine Jia, Tapan Maniar, Birgit Huber, Dirk Nagorsen, Hagop Kantarjian, Stephen J. Forman

Blood (2014) 124 (21): 965.

https://doi.org/10.1182/blood.V124.21.965.965

Published: 2014

Journal Articles

An Evaluation of Molecular Response in a Phase 2 Open-Label, Multicenter Confirmatory Study in Patients (pts) with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Receiving Treatment with the BiTE ® Antibody Construct Blinatumomab

Nicola Goekbuget, Hagop Kantarjian, Monika Brüggemann, Anthony Stein, Ralf C. Bargou, Hervé Dombret, Adele K. Fielding, Leonard Heffner, Françoise Rigal-Huguet, Mark Litzow, Susan O'Brien, Gerhard Zugmaier, Catherine Jia, Tapan Maniar, Birgit Huber, Dirk Nagorsen, Stephen J. Forman, Max S. Topp

Blood (2014) 124 (21): 3704.

https://doi.org/10.1182/blood.V124.21.3704.3704

Published: 2014

NARROW

Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma

CD200 Expression on Multiple Myeloma Cells Induces Attenuation of T Cell-Mediated Cytotoxicity Via DOK2

Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML

Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)

Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness

Activated Ral and Mutated RAS Are Independent Drivers of Multiple Myeloma Cell Survival.

Health-Related Quality of Life in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia and Minimal Residual Disease Treated with Blinatumomab

Implications of TP53 alterations for Therapy Response in Multiple Myeloma

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

RAL Mediates Multiple Myeloma Cell Survival Independently of Oncogenic RAS

Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking

Pathogenesis-Based Development of Potential Mitigation Strategies for Blinatumomab-Associated Neurologic Events (NEs)

Parallel Evolution of Multiple PSMB5 mutations in a Myeloma Patient Treated with Bortezomib

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Bispecific T-Cell Engager Antibody Construct Blinatumomab Shows Durable Response in a Long-Term Follow-up Analysis of 38 NHL Patients Treated in a Phase I Trial

Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

Treatment with Anti-CD19 BiTE ® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE ® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

An Evaluation of Molecular Response in a Phase 2 Open-Label, Multicenter Confirmatory Study in Patients (pts) with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Receiving Treatment with the BiTE ® Antibody Construct Blinatumomab

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only